

Brilliant Violet 605™ anti-mouse CD4 Antibody

Catalog# / Size	100547 / 125 µL 100548 / 50 µg
Clone	RM4-5
Regulatory Status	RUO
Other Names	L3T4, T4
Isotype	Rat IgG2a, κ
Description	CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Rat
Immunogen	BALB/c mouse thymocytes
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration	µg sizes: 0.2 mg/mL µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	<p>Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.</p> <p>Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.</p> <p>Learn more about Brilliant Violet™.</p> <p>This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.</p>
Excitation Laser	Violet Laser (405 nm)
Application Notes	The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4 ⁺ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include:

blocking of ligand binding, *in vivo* depletion of CD4⁺ cells¹, and immunohistochemistry of acetone-fixed frozen tissue sections^{2,3,11} and paraffin-embedded sections¹¹. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

(PubMed link indicates BioLegend citation)

1. Kruisbeek AM. 1991. *In Curr. Protocols Immunol.* pp. 4.1.1-4.1.5. (Block, Deplete)
2. Nitta H, *et al.* 1997. *Cell Vision* 4:73. (IHC)
3. Fan WY, *et al.* 2001. *Exp. Biol. Med.* 226:1045.
4. Muraille E, *et al.* 2003. *Infect. Immun.* 71:2704. (IHC)
5. León-Ponte M, *et al.* 2007. *Blood* 109:3139. (FC)
6. Bourdeau A, *et al.* 2007. *Blood* doi:10.1182/blood-2006-08-044370. (FC)
7. Matsumoto M, *et al.* 2007. *J. Immunol.* 178:2499. [PubMed](#)
8. Shigeta A, *et al.* 2008. *Blood* 112:4915. [PubMed](#)
9. Zaborsky N, *et al.* 2010. *J. Immunol.* 184:725. [PubMed](#)
10. Rodrigues-Manzanet R, *et al.* 2010. *P. Natl Acad Sci USA* 107:8706. [PubMed](#)
11. Whiteland JL, *et al.* 1995. *J. Histochem. Cytochem.* 43:313. (IHC)

Product Citations

1. Yu-Han Chang *et al.* 2017. *Immunity.* 47(5):943-958. [PubMed](#)
2. Komuczki J, *et al.* 2019. *Immunity.* 50:1289. [PubMed](#)
3. Metzger R, *et al.* 2019. *Front Oncol.* 1.070138889. [PubMed](#)
4. Flamar AL, *et al.* 2020. *Immunity.* 52(4):606-619.e6. [PubMed](#)
5. Schädlich IS, *et al.* 2022. *iScience.* 25:104470. [PubMed](#)
6. Wang Y, *et al.* 2021. *Cancer Res.* 81:174. [PubMed](#)
7. Israelow B, *et al.* 2020. *bioRxiv.* [PubMed](#)
8. Herz J, *et al.* 2015. *J Exp Med.* 212: 1153 - 1169. [PubMed](#)
9. Vanderleyden I, *et al.* 2020. *Cell Rep.* 30:611. [PubMed](#)
10. Han SJ *et al.* 2017. *Immunity.* 47(6):1154-1168. [PubMed](#)
11. Lyons J, *et al.* 2018. *PLoS Biol.* 16:e2002417. [PubMed](#)
12. Webb LMC, *et al.* 2021. *Aging Cell.* 20:e13295. [PubMed](#)
13. Sano T, *et al.* 2021. *Cell Reports.* 36(8):109608. [PubMed](#)
14. Van Den Eeckhout B, *et al.* 2020. *NPJ Vaccines.* 5:64. [PubMed](#)
15. Cannons JL, *et al.* 2021. *Cell Rep.* 37:109804. [PubMed](#)
16. Pingili AK, *et al.* 2021. *Cell Reports.* 35(12):109285. [PubMed](#)
17. Delacher M, *et al.* 2021. *Immunity.* 54(4):702-720.e17. [PubMed](#)
18. Zhang S, *et al.* 2021. *Cell.* 184(8):2151-2166.e16. [PubMed](#)
19. Piper CJM, *et al.* 2020. *Cell Reports.* 29(7):1878-1892.e7. [PubMed](#)
20. Feizi N, *et al.* 2021. *Cell Death Dis.* 12:1026. [PubMed](#)
21. Ward E, Fu H, Marelli-Berg F 2017. *Methods Mol Biol.* 10.1007/978-1-4939-6931-9_15. [PubMed](#)
22. Lutes LK, *et al.* 2021. *eLife.* 10:00. [PubMed](#)
23. Wei SC, *et al.* 2019. *Immunity.* 50:1084. [PubMed](#)
24. Mukherjee D, *et al.* 2022. *Nat Commun.* 13:3747. [PubMed](#)
25. Marangoni F, *et al.* 2021. *Cell.* [PubMed](#)
26. Latif AL, *et al.* 2021. *Nat Commun.* 0.667361111. [PubMed](#)
27. Chao CC, *et al.* 2020. *Cell.* 179(7):1483-1498.e22. [PubMed](#)
28. Lyons J, *et al.* 2018. *Sci Signal.* 11. [PubMed](#)
29. Wiesner D, *et al.* 2015. *PLoS Pathog.* 11:1004701. [PubMed](#)
30. Muppidi J, *et al.* 2015. *J Exp Med.* 212: 2213 - 2222. [PubMed](#)
31. Koren N, *et al.* 2021. *Cell Host Microbe.* 29(2):197-209.e5. [PubMed](#)
32. Dikiy S, *et al.* 2021. *Immunity.* 54(5):931-946.e11. [PubMed](#)
33. Trotta E, *et al.* 2018. *Nat Med.* 24:1005. [PubMed](#)
34. Beom JY, *et al.* 2019. *J Nat Prod.* 82:2078. [PubMed](#)
35. Lovisa S, *et al.* 2020. *Sci Signal.* 13:00. [PubMed](#)
36. Hartwig T *et al.* 2018. *Cell reports.* 25(13):3564-3572. [PubMed](#)
37. Colliou N, *et al.* 2018. *Gut Microbes.* 9:279. [PubMed](#)
38. Cassidy BR, *et al.* 2020. *J Neuroinflammation.* 17:259. [PubMed](#)
39. Doron I, *et al.* 2021. *Cell.* 184(4):1017-1031.e14. [PubMed](#)
40. Linehan JL *et al.* 2018. *Cell.* 172(4):784-796. [PubMed](#)
41. Jyh Liang Hor, William R. Heath, Scott N. Mueller 2017. *Sci Rep.* 7:41091. [PubMed](#)
42. Brown CC, *et al.* 2020. *Cell.* 179(4):846-863.e24. [PubMed](#)
43. van Montfoort N, *et al.* 2018. *Cell.* 175:1744. [PubMed](#)
44. Bradley KC, *et al.* 2019. *Cell Rep.* 28:245. [PubMed](#)
45. Campbell C *et al.* 2018. *Immunity.* 48(6):1245-1257. [PubMed](#)
46. Lewis EL, *et al.* 2021. *Front Immunol.* 12:741518. [PubMed](#)
47. Sharma M, *et al.* 2020. *Circ Res.* 127:335. [PubMed](#)
48. Kemp V, *et al.* 2018. *Cancer Gene Ther.* 26:268. [PubMed](#)
49. Wu B, *et al.* 2020. *Int J Biol Sci.* 16:1526. [PubMed](#)
50. Camell CD, *et al.* 2020. *Cell Metabolism.* 30(6):1024-1039.e6. [PubMed](#)
51. Germundson DL, *et al.* 2022. *Front Allergy.* 3:870513. [PubMed](#)
52. Yan J, *et al.* 2020. *Cell Rep.* 107820:31. [PubMed](#)
53. Sheldon RD, *et al.* 2021. *Nat Protoc.* 16:4494. [PubMed](#)
54. Tummers B, *et al.* 2020. *Immunity.* 52(6):994-1006.e8. [PubMed](#)
55. Prizant H, *et al.* 2021. *Cell Reports.* 36(6):109523. [PubMed](#)
56. Bruder J, *et al.* 2017. *Mol Ther Methods Clin Dev.* 10.1016/j.omtm.2017.08.003. [PubMed](#)
57. Yang BH, *et al.* 2020. *Cell Reports.* 27(12):3629-3645.e6. [PubMed](#)
58. Klein JC, *et al.* 2017. *Nat Commun.* 8:14600. [PubMed](#)
59. Han Y, *et al.* 2022. *Int J Biol Sci.* 18:5653. [PubMed](#)

60. Alexandre YO, *et al.* 2020. Cell Reports. 33(13):108567. [PubMed](#)
61. Williams JB, *et al.* 2020. Nat Commun. 0.876388889. [PubMed](#)
62. McAndrews KM, *et al.* 2021. J Biol Chem. 296:100523. [PubMed](#)
63. Chakraborty M, *et al.* 2021. Cell Reports. 34(2):108609. [PubMed](#)
64. Ruscher R, *et al.* 2018. Bio Protoc. 8:e2757. [PubMed](#)
65. Urata S, *et al.* 2018. PLoS Pathog. 14:e1007172. [PubMed](#)
66. Maniati E, *et al.* 2020. Cell Rep. 30:525. [PubMed](#)
67. Wang S, *et al.* 2022. J Inflamm Res. 14:7107. [PubMed](#)
68. Wei Y, *et al.* 2021. Endocrinology. 162(8):. [PubMed](#)
69. Israelow B, *et al.* 2020. J Exp Med. 217:00:00. [PubMed](#)
70. Sebina I, *et al.* 2016. PLoS Pathog. 12:e1005999. [PubMed](#)
71. Collins N, *et al.* 2020. Cell. 178(5):1088-1101.e15.. [PubMed](#)
72. Baumann D, *et al.* 2020. Nat Commun. 1.969444444. [PubMed](#)
73. Silva DA, *et al.* 2019. Nature. 565:186. [PubMed](#)
74. Ravussin A, *et al.* 2018. Cell Rep. 24:1085. [PubMed](#)
75. Mangas KM, *et al.* 2020. Infect Immun. 88:. [PubMed](#)
76. Gaylo-Moynihan A *et al.* 2019. Immunity. 51(2):298-309 . [PubMed](#)
77. Van Den Eeckhout B, *et al.* 2020. NPJ Vaccines. 0.252777778. [PubMed](#)
78. Chao JL, *et al.* 2021. Cell Rep Med. 2:100399. [PubMed](#)
79. Dhayade S, *et al.* 2020. Nutrients. 12:. [PubMed](#)
80. Truckenbrod EN, *et al.* 2021. Elife. 10:. [PubMed](#)
81. Hackstein CP, *et al.* 2022. Nat Commun. 13:7472. [PubMed](#)
82. Baker GJ, *et al.* 2020. Cell Syst. 0.647222222. [PubMed](#)
83. Lee Y, *et al.* 2018. Antimicrob Agents Chemother. 62:00:00. [PubMed](#)
84. Sharma M, *et al.* 2019. Immunometabolism. 1. [PubMed](#)
85. Graham JB, *et al.* 2017. Curr Protoc Mouse Biol. 7:221. [PubMed](#)
86. Stotesbury C, *et al.* 2020. Aging Cell. 19:e13170. [PubMed](#)
87. Wang J, *et al.* 2020. Cell. 183(7):1867-1883.e26. [PubMed](#)
88. Li X, *et al.* 2018. Cell Host Microbe. 24:847. [PubMed](#)
89. Rappe JCF, *et al.* 2021. J Exp Med. 218:. [PubMed](#)
90. Kastenschmidt JM, *et al.* 2021. Cell Rep. 35:108997. [PubMed](#)
91. Spath S, *et al.* 2022. iScience. 25:104998. [PubMed](#)
92. Nascimento DC, *et al.* 2021. Immunity. .: [PubMed](#)
93. Harvey RE *et al.* 2017. Endocrinology. 158(7):2179-2189 . [PubMed](#)
94. Ge Y, *et al.* 2020. Mucosal Immunol. 13:34. [PubMed](#)
95. Young A, *et al.* 2017. Cancer Res. 77:4684. [PubMed](#)
96. Tsai S, *et al.* 2018. Cell Metab. 28:922. [PubMed](#)

RRID AB_11125962 (BioLegend Cat. No. 100547)
 AB_2563054 (BioLegend Cat. No. 100548)

Antigen Details

Structure	Ig superfamily, 55 kD
Distribution	Majority of thymocytes, T cell subset
Function	TCR co-receptor, T cell activation
Ligand/Receptor	MHC class II molecule
Cell Type	Dendritic cells, T cells, Thymocytes, Tregs
Biology Area	Immunology
Molecular Family	CD Molecules
Antigen References	1. Barclay A, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Bierer BE, <i>et al.</i> 1989. <i>Annu. Rev. Immunol.</i> 7:579. 3. Janeway CA. 1992. <i>Annu. Rev. Immunol.</i> 10:645.
Gene ID	12504


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD4, Biotin anti-mouse CD4, FITC anti-mouse CD4, PE anti-mouse CD4, PE/Cyanine5 anti-mouse CD4, Purified anti-mouse CD4, PE/Cyanine7 anti-mouse CD4, APC/Cyanine7 anti-mouse CD4, Alexa Fluor® 647 anti-mouse CD4, Alexa Fluor® 488 anti-mouse CD4, Pacific Blue™ anti-mouse CD4, Alexa Fluor® 700 anti-mouse CD4, PerCP anti-mouse CD4, PerCP/Cyanine5.5 anti-mouse CD4, Brilliant Violet 421™ anti-mouse CD4, APC/Fire™ 750 anti-mouse CD4, Brilliant Violet 570™ anti-mouse CD4, Brilliant Violet 605™ anti-mouse CD4, Brilliant Violet 650™ anti-mouse CD4, Brilliant Violet 711™ anti-mouse CD4, Brilliant Violet 785™ anti-mouse CD4, Brilliant Violet 510™ anti-mouse CD4, Purified anti-mouse CD4 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD4, TotalSeq™-A0001 anti-mouse CD4, TotalSeq™-B0001 anti-mouse CD4, TotalSeq™-C0001 anti-mouse CD4, Ultra-LEAF™ Purified anti-mouse CD4, Spark Violet™ 423 anti-mouse CD4 (L3T4) Antibody

Product Data



C57BL/6 mouse splenocytes were stained with CD3 PE and CD4 (clone RM4-5) Brilliant Violet 605™.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587